Cytokinetics, Incorporated Common Stock (NASDAQ: CYTK) last traded at $76.84, down 0.44% on the session. The quote above updates while this page is open; the figures below are drawn from Cytokinetics, Incorporated Common Stock’s own filings and are restated only when a new one is published.
Cytokinetics, Incorporated Common Stock trades on NASDAQ under the ticker CYTK. Its market capitalisation is $10.68 billion.
Valuation measures for Cytokinetics, Incorporated Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $10.68B |
|---|---|
| Enterprise value | $12.53B |
| Price / sales | 157.86 |
| Beta | 0.70 |
Trailing-twelve-month figures tagged in Cytokinetics, Incorporated Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $67.67M |
|---|---|
| Net income (TTM) | -$894.00M |
| EPS (TTM) | -$7.23 |
| Operating margin | -1046.12% |
| Cash | $255.27M |
Range and volume for CYTK over the past 52 weeks.
| 52-week high | $88.31 |
|---|---|
| 52-week low | $35.22 |
| Volume | 1.51M |
| Average volume | 2.03M |
| Previous close | $77.18 |
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.